laquinimod Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
immunomodulators, both stimulant/suppressive and stimulant 4825 248282-07-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nerventra
  • laquinimod
  • laquinimod sodium
  • ABR-215062 sodium
  • TV-5600
Laquinimod is an immunomodulator developed by Teva for oral treatment for multiple sclerosis.
  • Molecular weight: 356.81
  • Formula: C19H17ClN2O3
  • CLOGP: 2.97
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 60.85
  • ALOGS: -3.91
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 5, 2013 Ministry of Health of the Russian Federation Teva

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07XX10 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.66 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D08938 KEGG_DRUG
248281-84-7 SECONDARY_CAS_RN
CHEBI:134738 CHEBI
CHEMBL66092 ChEMBL_ID
CHEMBL2103814 ChEMBL_ID
C476223 MESH_SUPPLEMENTAL_RECORD_UI
7639 IUPHAR_LIGAND_ID
8089 INN_ID
DB06685 DRUGBANK_ID
908SY76S4G UNII
54677946 PUBCHEM_CID
C1260208 UMLSCUI

Pharmaceutical products:

None